Abstract
Background: Invasive aspergillosis (IA) is a life-threatening infection in immunocompromised patients, including those with hematologic malignancies and hematopoietic stem cell transplants. While adult IA has been well characterized, data on pediatric populations remain limited, and potential age-related differences are often overlooked in current management guidelines. Methods: We conducted a retrospective matched cohort study at a tertiary cancer center, evaluating IA cases diagnosed over a 31-year period. Pediatric patients (≤18 years) with proven or probable IA were matched 1:3 with adult IA cases based on year of diagnosis, underlying disease, and history of hematopoietic cell transplantation. We compared demographics, clinical presentation, diagnostic modalities, microbiology, antifungal prophylaxis, and treatment approaches between the two groups. Results: The study included 34 pediatric and 102 matched adult IA cases. Pediatric patients were significantly more likely to present with neutropenia (p = 0.04) and sinus involvement (p = 0.048). Serum galactomannan testing was more often positive in pediatric patients (p = 0.027), whereas bronchoalveolar lavage galactomannan was more frequently positive in adults (p = 0.003). Differences in antifungal prophylactic regimens were also observed. Conclusions: Our findings underscore significant age-related variations in IA epidemiology, diagnostics, and management. These results support the development of age-specific diagnostic algorithms and antifungal strategies.
1. Introduction
Invasive aspergillosis (IA) continues to pose a significant threat to immunocompromised pediatric patients, particularly those undergoing chemotherapy, hematopoietic stem cell transplantation (HSCT), or receiving immunosuppressive therapy [1]. Despite advancements in antifungal therapies and diagnostic modalities, IA continues to be associated with high morbidity and mortality across all age groups [1,2,3]. While the underlying risk factors for IA, such as prolonged neutropenia, corticosteroid use, and immunosuppressive therapies, are common to both pediatric and adult populations, emerging evidence suggests notable age-related differences in the epidemiology, clinical presentation, diagnostic challenges, and management strategies of IA [1,4]. These disparities are clinically significant, yet pediatric-specific data remain limited, often necessitating the extrapolation of adult-based guidelines to younger patients [4,5].
One of the primary challenges in managing pediatric IA lies in its diagnosis. Non-culture-based diagnostic assays, including serum galactomannan (GM) and β-D-glucan (BDG), which are integral to IA diagnosis, vary in performance metrics between age groups [6,7].
Therapeutic approaches to IA also differ between children and adults, influenced by pharmacokinetic and pharmacodynamic variations [8]. For instance, voriconazole, a first-line antifungal agent for IA, exhibits faster clearance rates in children, necessitating higher or more frequent dosing to achieve therapeutic levels [8,9]. Limited availability of suitable oral formulations for younger children and delayed regulatory approval of new medications for pediatric patients contribute to additional differences between adult and pediatric treatment and prevention strategies, and limit antifungal options for children.
Antifungal prophylaxis practices further highlight age-related differences. Children undergoing cancer treatment or HSCT are less likely to receive mold-active azole prophylaxis compared to adults, potentially influencing IA incidence and outcomes [4,10]. These prophylactic disparities may also affect the epidemiology of Aspergillus species encountered, with some studies noting a higher prevalence of non-fumigatus aspergillosis including Aspergillus flavus in pediatric cases [11,12].
Outcomes of IA in pediatric patients remain a subject of ongoing investigation. While some studies suggest comparable or even better survival rates in children than adults, others report high mortality, particularly in specific subgroups such as HSCT recipients [13,14]. This data highlights the necessity for comprehensive, age-stratified analyses to better inform clinical decision-making.
Given the evolving understanding of age-related differences in invasive aspergillosis, this study aimed to compare the epidemiology, diagnostic approaches, treatment strategies, and clinical outcomes of IA in pediatric versus adult patients undergoing cancer therapy or HSCT. Using a matched cohort from a tertiary cancer center, we sought to identify age-specific patterns that could inform more personalized management guidelines and ultimately enhance care across the lifespan.
2. Materials and Methods
2.1. Study Design and Patient Selection
We conducted a retrospective matched cohort study of patients diagnosed with invasive aspergillosis at The University of Texas MD Anderson Cancer Center between July 1993 and April 2024. IA was classified as proven or probable according to the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) criteria [15].
Within this period, we identified 34 pediatric patients (aged ≤ 18 years at diagnosis) with IA. Each pediatric case was matched with three adult patients (aged ≥ 19 years) from a pre-existing IA database, resulting in a 1:3 pediatric-to-adult ratio. Matching was based on the year of IA diagnosis (±1 year), cancer type (hematologic malignancy vs. solid tumor), and history of hematopoietic cell transplantation within one year prior to IA diagnosis. Adult comparators were selected through simple random sampling to ensure representativeness and minimize selection bias.
2.2. Data Collection
Clinical and demographic data were extracted from electronic medical records. Variables included patient age, sex, underlying malignancy, neutropenia status at the time of IA diagnosis, site of infection, galactomannan (GM) testing and culture results, treatment regimens, and outcomes.
Neutropenia was defined as an absolute neutrophil count (ANC) ≤ 500 cells/μL, and neutrophil recovery was defined as sustained ANC > 500 cells/μL for at least seven consecutive days. Sites of infection (e.g., pulmonary, sinus, central nervous system) were recorded based on clinical, microbiological, and imaging data documented at the time of diagnosis.
The primary outcomes were all-cause mortality and IA-attributable mortality at 6 and 12 weeks following diagnosis. IA-attributable mortality was defined as death occurring without evidence of clinical improvement and with no alternative cause identified. Therapeutic response at the end of antifungal therapy was also assessed, based on predefined institutional criteria that integrated clinical and microbiological evidence of resolution.
2.3. Data Management and Ethical Considerations
Data were securely entered into REDCap version 15.3.1, a web-based research data management platform. The study protocol was approved by the Institutional Review Board (IRB) at MD Anderson Cancer Center, PA17-0883 2023-10-17. Given the retrospective nature of the study and the use of de-identified data, informed consent was waived by the IRB.
2.4. Statistical Analysis
Chi-square or Fisher’s exact tests were used to compare categorical variables, as appropriate. The Wilcoxon rank-sum test was used to compare continuous variables. All tests were two-sided, with a significance level set at 0.05. Data analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Demographics and Risk Factors
We identified 34 pediatric patients (≤18 years) and matched them with 102 adult patients diagnosed with proven or probable invasive aspergillosis between 1993 and 2024. Pediatric patients had a median age of 14 years (range: 2–18), while adult patients had a median age of 54 years (range: 19–84). The gender distribution was not significantly different, although a higher proportion of children were male (71% vs. 54% in adults, p = 0.088).
Most patients (91%) had a hematologic malignancy, and approximately 40% of pediatric patients had undergone hematopoietic stem cell transplantation. Neutropenia at diagnosis was significantly more common in pediatric patients compared to adults (64% vs. 43%, p = 0.04), likely reflecting differences in treatment regimens or baseline immune suppression. Patterns of antifungal prophylaxis also differed notably: pediatric patients were more likely to be receiving prophylaxis at the time of diagnosis yet were less likely to be on mold-active azoles and more likely to be receiving echinocandins (34% vs. 10% in adults, p = 0.002) (Table 1).
Table 1.
Comparison of baseline characteristics of adult and pediatric patients with invasive aspergillosis.
3.2. Disease Characteristics and Diagnostics
Pulmonary involvement was the most common site of infection overall but was more frequently seen among adults (92% vs. 70% in children, p = 0.003). In contrast, sinus involvement was more frequent in pediatric patients (9% vs. 1%, p = 0.048). A total of three pediatric patients had sinus infections, one of which was caused by A. flavus.
Aspergillus galactomannan (GM) testing was performed in a subset of patients. Serum GM was conducted in 24% of adult patients and 47% of pediatric patients, while BAL GM testing was conducted in 35% of adults and 32% of pediatric patients. Serum galactomannan was more commonly positive among pediatric patients (88% vs. 54%, p = 0.027), whereas BAL galactomannan positivity was more frequently observed in adults (61% vs. 9%, p = 0.003), potentially reflecting differential diagnostic approaches or variations in disease localization.
Among culture-confirmed cases, A. flavus was the most isolated specie in pediatric patients (41%), followed by A. fumigatus (29%). In contrast, A. fumigatus predominated in adults (32%) (Table 2).
Table 2.
Comparison of diagnostic findings, treatment, and clinical outcomes in adult and pediatric patients with invasive aspergillosis.
3.3. Treatment and Outcomes
Pediatric patients were more often treated with antifungal monotherapy (65% vs. 56% in adults), while combination therapy was more frequently used in adults.
Regarding outcomes, ICU admission and mechanical ventilation rates were similar between groups. At 12 weeks, all-cause mortality was higher among pediatric patients (47% vs. 37% in adults), as was IA-attributable mortality (38% vs. 25%). However, these differences did not reach statistical significance.
4. Discussion
This matched cohort study provides a comprehensive comparison of invasive aspergillosis in pediatric and adult patients with cancer or hematopoietic stem cell transplantation over a 31-year period at a tertiary cancer center. The findings underscore notable age-related differences in clinical presentation, diagnostic approaches, antifungal prophylaxis, and outcomes, all of which point to the need for age-specific strategies in the management of IA.
Pediatric patients more frequently presented with neutropenia at the time of IA diagnosis, a finding that may reflect their higher exposure to intensive chemotherapy regimens or conditioning protocols for HSCT. Moreover, sinus involvement was significantly more common among pediatric patients (9% vs. 1%), a difference that may be attributed to anatomical factors, immune response variability, or environmental exposures that differ with age. In contrast, pulmonary IA was predominant in adults, consistent with literature emphasizing the lungs as the most common site of IA in immunocompromised adults [16]. In our cohort, pulmonary involvement was observed in 68% of pediatric cases, while another study reported pulmonary involvement in 40% of cases [17].
Differences in diagnostic outcomes were also observed between the two groups. Serum galactomannan testing was more frequently positive in children (88% vs. 54%), while BAL GM positivity was significantly higher in adults (61% vs. 9%). These differences may be influenced by the relative distribution of disease (e.g., more extrapulmonary involvement in children), the feasibility of conducting invasive procedures such as bronchoscopy in pediatric populations, and differing thresholds for initiating diagnostic testing. Prior studies have highlighted the limited sensitivity and specificity of galactomannan testing in children, which may stem from age-related differences in fungal burden, immune response, and diagnostic timing [6,18].
Antifungal prophylaxis strategies also differed notably between the groups. At the time of IA diagnosis, children were less likely receiving mold-active azole prophylaxis and more likely to be on echinocandins (34% vs. 10%). This may reflect ongoing concerns regarding azole pharmacokinetics in pediatric populations, including faster drug clearance, the need for higher dosing, and challenges related to therapeutic drug monitoring [9,19]. Echinocandins, though not first-line therapy for IA treatment, are often favored in pediatric patients for their safety profile and more predictable pharmacokinetics [20].
Microbiological findings revealed that A. flavus was isolated more frequently in pediatric patients (41%) than in adults (22%), while A. fumigatus remained the predominant species among adults. The higher prevalence of A. flavus in children has been documented in prior studies and may reflect differences in geographic exposure, host susceptibility, or local environmental conditions [11,12]. Other pediatric studies have reported A. fumigatus as the most commonly isolated species in children [21,22].
In our cohort, differences in mortality between pediatric and adult patients did not reach statistical significance. This finding is noteworthy, especially in light of previous studies that have reported improved survival outcomes in pediatric populations [23,24]. The increased mortality observed among pediatric patients in our study may be attributed to delayed recognition of IA, less frequent use of mold-active azole prophylaxis, differences in pharmacokinetics affecting antifungal efficacy, or more aggressive underlying malignancies.
This study’s retrospective design and single-center setting introduce inherent limitations, including possible changes in diagnostic criteria, and treatment protocols over time. Furthermore, the relatively small pediatric sample size may limit the statistical power to detect significant differences in outcomes or risk factors.
5. Conclusions
This matched cohort study underscores important age-related differences in invasive aspergillosis among cancer and HSCT patients. Pediatric patients were more likely to present with neutropenia, and sinus involvement. Diagnostic patterns also differed, with higher serum galactomannan positivity in children and more BAL galactomannan positivity in adults. These findings highlight the need for tailored diagnostic and therapeutic strategies in pediatric IA and support further prospective, age-stratified studies to inform evidence-based clinical guidelines.
Author Contributions
Conceptualization, S.W. and I.I.R.; Methodology, S.W., R.Z., A.-M.C., R.H. and I.I.R.; Formal analysis, Y.J.; Data curation, S.W., A.-M.C., H.D., R.Z. and R.H.; Writing—original draft, S.W.; Writing—review & editing, S.W., R.Z., A.-M.C., R.H., R.S. and I.I.R. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
This study was approved by the institutional review board at MD Anderson, PA17-0883 2023-10-17.
Informed Consent Statement
Patient consent was waived due to the retrospective nature of this study.
Data Availability Statement
The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.
Acknowledgments
Editing was provided by Sarah Bronson, ELS, of the Research Medical Library at The University of Texas MD Anderson Cancer Center.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Nivoix, Y.; Velten, M.; Letscher-Bru, V.; Moghaddam, A.; Natarajan-Amé, S.; Fohrer, C.; Lioure, B.; Bilger, K.; Lutun, P.; Marcellin, L.; et al. Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis. Clin. Infect. Dis. 2008, 47, 1176–1184. [Google Scholar] [CrossRef] [PubMed]
- Taccone, F.S.; Van den Abeele, A.-M.; Bulpa, P.; Misset, B.; Meersseman, W.; Cardoso, T.; Paiva, J.-A.; Blasco-Navalpotro, M.; De Laere, E.; Dimopoulos, G.; et al. Epidemiology of invasive aspergillosis in critically ill patients: Clinical presentation, underlying conditions, and outcomes. Crit. Care 2015, 19, 7. [Google Scholar] [CrossRef]
- Dagher, H.; Chaftari, A.M.; Haddad, A.; Jiang, Y.; Shrestha, J.; Sherchan, R.; Lamie, P.; Makhoul, J.; Chaftari, P.; Hachem, R.; et al. Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment: 30-Year Experience in Hematologic Malignancy Patients. J. Fungi 2025, 11, 160. [Google Scholar] [CrossRef]
- Lehrnbecher, T.; Fisher, B.T.; Phillips, B.; Beauchemin, M.; Carlesse, F.; Castagnola, E.; Duong, N.; Dupuis, L.L.; Fioravantti, V.; Groll, A.H.; et al. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. J. Clin. Oncol. 2020, 38, 3205–3216. [Google Scholar] [CrossRef]
- Terlizzi, V.; Motisi, M.A.; Pellegrino, R.; Galli, L.; Taccetti, G.; Chiappini, E. Management of pulmonary aspergillosis in children: A systematic review. Ital. J. Pediatr. 2023, 49, 39. [Google Scholar] [CrossRef]
- Lehrnbecher, T.; Robinson, P.D.; Fisher, B.T.; Castagnola, E.; Groll, A.H.; Steinbach, W.J.; Zaoutis, T.E.; Negeri, Z.F.; Beyene, J.; Phillips, B.; et al. Galactomannan, β-D-Glucan, and Polymerase Chain Reaction–Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2016, 63, 1340–1348. [Google Scholar] [CrossRef]
- Badiee, P.; Alborzi, A.; Karimi, M.; Pourabbas, B.; Haddadi, P.; Mardaneh, J.; Moieni, M. Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J. Infect. Dev. Ctries. 2012, 6, 352–357. [Google Scholar] [CrossRef]
- Michael, C.; Bierbach, U.; Frenzel, K.; Lange, T.; Basara, N.; Niederwieser, D.; Mauz-Körholz, C.; Preiss, R. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob. Agents Chemother. 2010, 54, 3225–3232. [Google Scholar] [CrossRef] [PubMed]
- Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. Antimicrob. Agents Chemother. 2010, 54, 4116–4123. [Google Scholar] [CrossRef]
- Science, M.; Robinson, P.D.; MacDonald, T.; Rassekh, S.R.; Dupuis, L.L.; Sung, L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr. Blood Cancer 2014, 61, 393–400. [Google Scholar] [CrossRef] [PubMed]
- Abbasi, S.; Shenep, J.L.; Hughes, W.T.; Flynn, P.M. Aspergillosis in Children with Cancer: A 34-Year Experience. Clin. Infect. Dis. 1999, 29, 1210–1219. [Google Scholar] [CrossRef] [PubMed]
- Walmsley, S.; Devi, S.; King, S.; Schneider, R.; Richardson, S.; Ford-Jones, L. Invasive Aspergillus infections in a pediatric hospital: A ten-year review. Pediatr. Infect. Dis. J. 1993, 12, 673–682. [Google Scholar] [CrossRef]
- Al Dhaheri, F.; Lee, R.A.; Sharma, T.S.; Nakamura, M.M.; Marty, F.M. Epidemiology and outcomes of invasive aspergillosis among pediatric immunocompromised patients: A 12-year single-center experience. Med. Mycol. 2022, 60, myac014. [Google Scholar] [CrossRef]
- Shekhova, E.; Salazar, F.; Da Silva Dantas, A.; Chakraborty, T.; Wooding, E.L.; White, P.L.; Warris, A. Age difference of patients with and without invasive aspergillosis: A systematic review and meta-analysis. BMC Infect. Dis. 2024, 24, 220. [Google Scholar] [CrossRef] [PubMed]
- De Pauw, B.; Walsh, T.J.; Donnelly, J.P.; Stevens, D.A.; Edwards, J.E.; Calandra, T.; Pappas, P.G.; Maertens, J.; Lortholary, O.; Kauffman, C.A.; et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008, 46, 1813–1821. [Google Scholar] [CrossRef]
- Kousha, M.; Tadi, R.; Soubani, A.O. Pulmonary aspergillosis: A clinical review. Eur. Respir. Rev. 2011, 20, 156–174. [Google Scholar] [CrossRef]
- Rubio, P.M.; Sevilla, J.; González-Vicent, M.; Lassaletta, A.; Cuenca-Estrella, M.; Díaz, M.A.; Riesco, S.; Madero, L. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study. J. Pediatr. Hematol. Oncol. 2009, 31, 642–646. [Google Scholar] [CrossRef] [PubMed]
- Hsu, A.J.; Tamma, P.D.; Zhang, S.X. Challenges with Utilizing the 1,3-Beta-d-Glucan and Galactomannan Assays To Diagnose Invasive Mold Infections in Immunocompromised Children. J. Clin. Microbiol. 2021, 59. [Google Scholar] [CrossRef]
- Hsu, A.J.; Tamma, P.D.; Fisher, B.T. Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children. Antimicrob. Agents Chemother. 2022, 66, e02156-21. [Google Scholar] [CrossRef]
- VandenBussche, H.L.; Van Loo, D.A. A Clinical Review of Echinocandins in Pediatric Patients. Ann. Pharmacother. 2010, 44, 166–177. [Google Scholar] [CrossRef]
- Wattier, R.L.; Dvorak, C.C.; Hoffman, J.A.; Brozovich, A.A.; Bin-Hussain, I.; Groll, A.H.; Castagnola, E.; Knapp, K.M.; Zaoutis, T.E.; Gustafsson, B.; et al. A Prospective, International Cohort Study of Invasive Mold Infections in Children. J. Pediatr. Infect. Dis. Soc. 2015, 4, 313–322. [Google Scholar] [CrossRef] [PubMed]
- Burgos, A.; Zaoutis, T.E.; Dvorak, C.C.; Hoffman, J.A.; Knapp, K.M.; Nania, J.J.; Prasad, P.; Steinbach, W.J. Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008, 121, e1286–e1294. [Google Scholar] [CrossRef]
- Castagnola, E.; Cesaro, S.; Giacchino, M.; Livadiotti, S.; Tucci, F.; Zanazzo, G.; Caselli, D.; Caviglia, I.; Parodi, S.; Rondelli, R.; et al. Fungal Infections in Children With Cancer: A Prospective, Multicenter Surveillance Study. Pediatr. Infect. Dis. J. 2006, 25, 634–639. [Google Scholar] [CrossRef] [PubMed]
- Martins, A.C.; Psaltikidis, E.M.; Cristiano de Lima, T.; Fagnani, R.; Gomide, H.C.A.C.; Gilli, F.H.; Schreiber, A.Z.; de Oliveira Conterno, L.; Matsuzawa, T.; Watanabe, A.; et al. Clinical outcomes of aspergillosis among paediatric and adult inpatients: A multicentre study in a Brazilian metropolitan area. J. Med. Mycol. 2023, 33, 101435. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).